Zogenix's treatment for rare epilepsy meets advanced study goal

(Reuters) – Zogenix Inc said on Thursday its drug to treat Dravet syndrome, a rare form of epilepsy, met the main goal of a late-stage trial. The study, the second late-stage trial of the drug, found that the treatment led to a reduction in reduction in mean monthly seizures, when compared with a placebo.


Related posts

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.